We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Analysis & Separations

Stay up to date on the topics that matter to you

IsoPlexis

IsoPlexis is dedicated to accelerating the fight against cancer and a range of our toughest diseases by producing the world’s most precise, award-winning detection systems. By revealing unique immune biomarkers in small subsets of cells, they are advancing immunotherapies and targeted therapies to a more precise and personalized stage.

Latest IsoPlexis Content

Industry Insight

Identifying Risk Factors for Long COVID With Single-Cell Proteomics

In this interview we speak to Sean Mackay, CEO of IsoPlexis, to discuss how single-cell functional proteomics have helped researchers understand the risk factors behind long COVID.

Never miss a story

with the Breaking Science News daily newsletter